Semaglutide at BMI 26: what the evidence and UK licensing actually say

What the licensed indications actually require at this BMI

The MHRA-approved licence for Wegovy, as set out in its Summary of Product Characteristics on the eMC, permits semaglutide for weight management in two distinct groups: adults with a BMI of 30 or above, and adults with a BMI between 27 and 29.9 who have at least one weight-related comorbidity. A BMI of 26 does not meet either criterion in the standard wording. That is the regulatory baseline, and it matters, because prescribers in the UK work within it.

The conditions that count under the 27–29.9 threshold include type 2 diabetes, prediabetes, raised blood pressure, dyslipidaemia (high cholesterol or triglycerides) and obstructive sleep apnoea, among others. If someone at BMI 26 carries one of those diagnoses, the conversation shifts from 'does this medicine apply to me at all' to 'does my BMI fall inside a separately adjusted range', which brings in the ethnic-background question below.

NHS guidance on BMI requirements for semaglutide outlines this two-tier structure clearly. The key practical point is that a BMI of 26 without any qualifying condition sits outside the licence; a BMI of 26 with a relevant comorbidity is still below the 27 floor, so it remains outside in most cases. A full clinical assessment is the only way to know for certain how your individual picture is read.

How ethnic-background adjustments affect the threshold, and whether they reach BMI 26

UK clinical guidance recognises that BMI is a blunt tool when applied across different ethnic groups. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, weight-related health risks tend to appear at lower BMI values. In response, NHS England and NICE apply thresholds that are typically 2.5 kg/m² lower than the standard figures.

In practice, that adjustment moves the lower qualifying threshold from 27 down to 24.5 when a weight-related condition is present. A BMI of 26 with a qualifying condition, in one of those ethnic-background groups, sits above that adjusted 24.5 floor, and would therefore meet the licence criterion. This is not a loophole; it reflects a genuine difference in how obesity-related risk distributes across populations, and it is written into the guidance explicitly.

That said, meeting the BMI threshold is necessary but not sufficient. A prescriber still needs to assess the whole clinical picture: what the condition is, how it is being managed, what other medicines you take. Our page on who can take semaglutide covers the full eligibility framework, including contraindications that rule treatment out regardless of BMI.

What the trial evidence says, and why it was not run at BMI 26

The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above, or 27 or above with a weight-related condition, and found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That evidence base is what the NICE appraisal of semaglutide (TA875) drew on, and it was specifically conducted in the populations for whom the licence was then sought.

There is no large-scale trial of semaglutide for weight management in people with a BMI of 26 without a comorbidity, because that was not the population the medicine was developed to treat in this indication. Using evidence beyond the population in which it was generated introduces uncertainty, and responsible prescribing stays close to the evidence. A closer look at semaglutide use at normal or near-normal BMI discusses what is and is not known for people outside the standard licensed range.

For context on how Wegovy compares with other options that might be considered at lower BMI values, the weight management overview covers the landscape plainly.

What happens at a consultation if your BMI is 26

A genuine clinical consultation is not a BMI calculator with a yes/no output. A GPhC-registered prescriber reviews your weight history, any diagnoses you carry, current medications, and whether your BMI measurement itself is accurate and recent, a home scale and a GP scale can read differently, and weight can shift between months.

If you do have a qualifying condition and your ethnic background means the adjusted threshold applies, a prescriber can work through that properly. If neither condition applies at BMI 26, an honest consultation will say so, and may point toward other support, including lifestyle programmes, that are appropriate at this point. That is what clinical review should do.

If you are wondering about costs before starting a conversation, our guide to getting Wegovy through a UK pharmacy covers how private prescriptions work and what to expect from a reputable service. And if you are curious about where your BMI sits relative to the full range of thresholds, the Wegovy BMI guide sets it all out. A full overview of who can use semaglutide for weight loss in the UK is also worth reading before you start.

Semaglutide is a prescription-only medicine. The prescriber decides suitability, not a headline BMI figure and not an online eligibility checker. If you want a proper clinical assessment rather than a general answer, speak to our prescribers through a free consultation; they will tell you clearly where you stand.